US pharma giants Pfizer and Moderna would not have got approval for their COVID-19 vaccines had they conducted phase-three clinical trials during the second coronavirus wave which was driven by the Delta variant, Krishna Ella, Chairman and Managing Director of Bharat Biotech said on Wednesday.
Hyderabad-based Bharat Biotech, the manufacturer of COVID-19 Covaxin, said the efficacy of its vaccine would have been 85 percent against the original strain of the virus — the one that was first detected in China.
News Source: Mint
